Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. (ARDS): 7 pipeline candidates · ~5 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.9 months
D/E -1.55 · 0% dilution
Lead: Phase 3
7 candidates
N/A
N/A
A transparent, data-derived signal for Aridis Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$9K
Cash
$535K
Quarterly Burn
$983K
Runway
4.9 mo
Revenue
$417K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Frequently asked questions
How many drug candidates are in Aridis Pharmaceuticals, Inc.'s pipeline?
Aridis Pharmaceuticals, Inc. (ARDS) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aridis Pharmaceuticals, Inc.'s lead drug candidate?
Aridis Pharmaceuticals, Inc.'s most advanced tracked candidate is AR-101 (Phase 2) for Adjunctive treatment (with SOC antibiotics) for HAP and VAP caused by Pseudomonas aeruginosa serotype O11..
What is Aridis Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aridis Pharmaceuticals, Inc. has approximately 4.9 months of cash runway.
What is Aridis Pharmaceuticals, Inc.'s market capitalization?
Aridis Pharmaceuticals, Inc.'s market capitalization is approximately $9K.
Who is the CEO of Aridis Pharmaceuticals, Inc.?
Dr. Vu L. Truong Ph.D. is the chief executive officer of Aridis Pharmaceuticals, Inc. (ARDS).
Get the full picture on Aridis Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.